These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 38402212)
21. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794 [TBL] [Abstract][Full Text] [Related]
22. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Jothi M; Mal M; Keller C; Mal AK Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448 [TBL] [Abstract][Full Text] [Related]
23. The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition. Gonzalez Curto G; Der Vartanian A; Frarma YE; Manceau L; Baldi L; Prisco S; Elarouci N; Causeret F; Korenkov D; Rigolet M; Aurade F; De Reynies A; Contremoulins V; Relaix F; Faklaris O; Briscoe J; Gilardi-Hebenstreit P; Ribes V PLoS Genet; 2020 Nov; 16(11):e1009164. PubMed ID: 33175861 [TBL] [Abstract][Full Text] [Related]
24. Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs. Manceau L; Richard Albert J; Lollini PL; Greenberg MVC; Gilardi-Hebenstreit P; Ribes V PLoS Genet; 2022 May; 18(5):e1009782. PubMed ID: 35604932 [TBL] [Abstract][Full Text] [Related]
25. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413 [TBL] [Abstract][Full Text] [Related]
27. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway. Schmitt-Ney M; Camussi G PLoS One; 2015; 10(3):e0121474. PubMed ID: 25806826 [TBL] [Abstract][Full Text] [Related]
28. Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2. Song Z; Gong B; Qu T; Chen Y; Zhao G; Jin Y; Zhao Q Biomed Pharmacother; 2024 Aug; 177():117126. PubMed ID: 38996706 [TBL] [Abstract][Full Text] [Related]
29. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group. Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499 [TBL] [Abstract][Full Text] [Related]
30. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931 [TBL] [Abstract][Full Text] [Related]
31. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH; Mercado GE; Laé M; Ladanyi M Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015 [TBL] [Abstract][Full Text] [Related]